Randomized Trials Are Needed for Transcatheter Mitral Valve Replacement
Recommended Citation
Rogers JH, Sorajja P, Thourani VH, Sharma RP, Chehab B, Cowger J, Heimansohn D, Badhwar V, Guerrero M, and Ailawadi G. Randomized Trials Are Needed for Transcatheter Mitral Valve Replacement. JACC Cardiovasc Interv 2021; 14(18):2039-2046.
Document Type
Article
Publication Date
9-27-2021
Publication Title
JACC Cardiovasc Interv
Abstract
Transcatheter mitral valve replacement (TMVR) is a new therapy for treating symptomatic mitral regurgitation (MR) and stenosis. The proposed benefit of TMVR is the predictable, complete elimination of MR, which is less certain with transcatheter repair technologies such as TEER (transcatheter edge-to-edge repair). The potential benefit of MR elimination with TMVR needs to be rigorously evaluated against its risks which include relative procedural invasiveness, need for anticoagulation, and chronic structural valve deterioration. Randomized controlled trials (RCTs) are a powerful method for evaluating the safety and effectiveness of TMVR against current standard of care transcatheter therapies, such as TEER. RCTs not only help with the assessment of benefits and risks, but also with policies for determining operator or institutional requirements, resource utilization, and reimbursement. In this paper, the authors provide recommendations and considerations for designing pivotal RCTs for first-in-class TMVR devices.
PubMed ID
34556279
Volume
14
Issue
18
First Page
2039
Last Page
2046
